Furthermore,
generic of plaquenil has demonstrated potential in the field of oncology, particularly in the management of certain malignancies characterized by immune dysregulation. Preclinical studies have suggested its efficacy in enhancing the antitumor immune response and sensitizing cancer cells to immunotherapy. By targeting immune checkpoints and inflammatory pathways, Plaquenil may augment the effectiveness of existing cancer treatments and overcome resistance mechanisms, offering new avenues for improving outcomes in patients with refractory malignancies.